Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03038711 · ClinicalTrials.gov registry record · Phase 1
A Multiple Dose Study to Assess the Safety and Tolerability of BMS-986166 in Healthy Volunteers
A Phase 1 study, sponsored by Bristol-Myers Squibb.
- Completed
- Registry status
- Phase 1
- Development phase
- 213
- Enrollment target
NCT03038711 is a Phase 1 study that has completed, run by Bristol-Myers Squibb. The registered enrollment target is 213 participants.
The verdict
NCT03038711, a Phase 1 study, has completed, sponsored by Bristol-Myers Squibb.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 213 participants
- Enrollment target
Study Summary
The purpose of this study is to understand if multiple oral doses of BMS-986166 are safe and well tolerated in healthy patients.
Interventions
- DRUG BMS-986166
- OTHER Placebo matching BMS-986166
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 213 participants |
| Start Date | 2017-02-01 |
| Est. Completion | 2017-08-10 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03038711
The ClinicalTrials.gov registry entry for NCT03038711 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 213 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Bristol-Myers Squibb, which has 1,025 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which BMS-986166 is the first listed.
NCT03038711 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03038711 about?
NCT03038711 is a clinical study titled "A Multiple Dose Study to Assess the Safety and Tolerability of BMS-986166 in Healthy Volunteers". The purpose of this study is to understand if multiple oral doses of BMS-986166 are safe and well tolerated in healthy patients.
What is the current status of trial NCT03038711?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 213 participants. The study started on 2017-02-01. Estimated completion is 2017-08-10.
What interventions are being tested in trial NCT03038711?
The interventions under investigation include: BMS-986166 (DRUG), Placebo matching BMS-986166 (OTHER).
Who is sponsoring clinical trial NCT03038711?
This trial is sponsored by Bristol-Myers Squibb, which has 1,025 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.